Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (Q37360367)

19 August 2017

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (English)

1 reference

19 August 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Patrick G Gavin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Zachary D Horne

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Sandra M. Swain

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Soonmyung Paik

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Eleftherios P Mamounas

24

object named as

Eleftherios P Mamounas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Katherine L Pogue-Geile

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Noriko Tanaka

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Hanna Bandos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Debora Fumagalli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Lynn C Goldstein

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Nour Sneige

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Eike Burandt

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Yusuke Taniyama

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Olga L Bohn

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Ahwon Lee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Seung-Il Kim

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Megan L Reilly

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Matthew Y Remillard

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Nicole L Blackmon

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Seong-Rim Kim

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Priya Rastogi

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Louis Fehrenbacher

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Edward H Romond

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

D Lawrence Wickerham

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Charles E Geyer

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Joseph P Costantino

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Norman Wolmark

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Chungyeul Kim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

21 November 2013

1 reference

Journal of the National Cancer Institute

19 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

1782-1788

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

8 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Supervised risk predictor of breast cancer based on intrinsic subtypes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Direct multiplexed measurement of gene expression with color-coded probe pairs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Patterns of treatment effects in subsets of patients in clinical trials

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848987

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24262440

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 status and benefit from adjuvant trastuzumab in breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24262440

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJT321

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262440%20AND%20SRC:MED&resulttype=core&format=json